{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:44:23Z","timestamp":1780735463346,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04212-z","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T17:51:02Z","timestamp":1743184262000},"page":"308-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the prognostic significance of the pre-treatment neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios in 177Lu-DOTATATE PRRT treated patients with advanced metastatic neuroendocrine tumors"],"prefix":"10.1007","volume":"89","author":[{"given":"Mahesh K.","family":"Padwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir K.","family":"Nazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul V.","family":"Parghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"4212_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.anndiagpath.2017.04.005","volume":"29","author":"JY Kim","year":"2017","unstructured":"JY Kim, SM Hong, JY Ro, Recent updates on grading and classification of neuroendocrine tumors. Ann. Diagn. Pathol. 29, 11\u201316 (2017). https:\/\/doi.org\/10.1016\/j.anndiagpath.2017.04.005.","journal-title":"Ann. Diagn. Pathol."},{"key":"4212_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"S Das, A Dasari, Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?. Curr. Oncol. Rep 23, 43 (2021). https:\/\/doi.org\/10.1007\/s11912-021-01029-7.","journal-title":"Curr. Oncol. Rep"},{"key":"4212_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cpet.2022.10.002","volume":"18","author":"A Ramesh","year":"2023","unstructured":"A Ramesh, A Chatterjee, RM Subramaniam, Neuroendocrine neoplasms: epidemiology, diagnosis, and management. PET. Clin. 18, 161\u2013168 (2023). https:\/\/doi.org\/10.1016\/j.cpet.2022.10.002.","journal-title":"PET. Clin."},{"key":"4212_CR4","doi-asserted-by":"publisher","first-page":"20201041","DOI":"10.1259\/bjr.20201041","volume":"94","author":"K Sitani","year":"2021","unstructured":"K Sitani, RV Parghane, S Talole, S Basu, Long-term outcome of indigenous (177)Lu-DOTATATE PRRT in patients with metastatic advanced neuroendocrine tumours: a single institutional observation in a large tertiary care setting. Br. J. Radiol. 94, 20201041 (2021). https:\/\/doi.org\/10.1259\/bjr.20201041.","journal-title":"Br. J. Radiol."},{"key":"4212_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cpet.2022.11.009","volume":"18","author":"VS Jayaprakasam","year":"2023","unstructured":"VS Jayaprakasam, L Bodei, Neuroendocrine tumor therapy response assessment. PET. Clin. 18, 267\u2013286 (2023). https:\/\/doi.org\/10.1016\/j.cpet.2022.11.009.","journal-title":"PET. Clin."},{"key":"4212_CR6","doi-asserted-by":"publisher","first-page":"1064145","DOI":"10.3389\/fsurg.2023.1064145","volume":"10","author":"A Koffas","year":"2023","unstructured":"A Koffas, A Giakoustidis, A Papaefthymiou, P Bangeas, D Giakoustidis, VN Papadopoulos, C Toumpanakis, Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. Front. Surg. 10, 1064145 (2023). https:\/\/doi.org\/10.3389\/fsurg.2023.1064145.","journal-title":"Front. Surg."},{"key":"4212_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","volume":"71","author":"ME Caplin","year":"2021","unstructured":"ME Caplin, M Pavel, AT Phan, JB \u0106wik\u0142a, E Sedl\u00e1\u010dkov\u00e1, X-MT Thanh, EM Wolin, P Ruszniewski, C.I. on behalf of the, Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine 71, 502\u2013513 (2021). https:\/\/doi.org\/10.1007\/s12020-020-02475-2.","journal-title":"Endocrine"},{"key":"4212_CR8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","volume":"15","author":"L Urso","year":"2023","unstructured":"L Urso, A Nieri, L Uccelli, A Castello, P Artioli, C Cittanti, MC Marzola, L Florimonte, M Castellani, S Bissoli, F Porto, A Boschi, L Evangelista, M Bartolomei, Lutathera\u00ae Orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE. Pharmaceutics 15, 1110 (2023). https:\/\/doi.org\/10.3390\/pharmaceutics15041110.","journal-title":"Pharmaceutics"},{"key":"4212_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","volume":"157","author":"M Pavel","year":"2021","unstructured":"M Pavel, JB \u0106wik\u0142a, C Lombard-Bohas, I Borbath, T Shah, UF Pape, J Capdevila, F Panzuto, X-M Truong Thanh, A Houchard, P Ruszniewski, Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur. J. Cancer 157, 403\u2013414 (2021). https:\/\/doi.org\/10.1016\/j.ejca.2021.06.056.","journal-title":"Eur. J. Cancer"},{"key":"4212_CR10","doi-asserted-by":"publisher","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","volume":"4","author":"Z Xu","year":"2021","unstructured":"Z Xu, L Wang, S Dai, M Chen, F Li, J Sun, F Luo, Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw. Open. 4, e2124750\u2013e2124750 (2021). https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24750.","journal-title":"JAMA Netw. Open."},{"key":"4212_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000534035","volume":"114","author":"NC Helderman","year":"2023","unstructured":"NC Helderman, M Suerink, G Kilin\u00e7, JGvan den Berg, M Nielsen, MET Tesselaar, Relation between WHO classification and location- and functionality-based classifications of neuroendocrine neoplasms of the digestive tract. Neuroendocrinology 114, 120\u2013133 (2023). https:\/\/doi.org\/10.1159\/000534035.","journal-title":"Neuroendocrinology"},{"key":"4212_CR12","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","volume":"7","author":"RD Dolan","year":"2017","unstructured":"RD Dolan, J Lim, ST McSorley, PG Horgan, DC McMillan, The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci. Rep 7, 16717 (2017). https:\/\/doi.org\/10.1038\/s41598-017-16955-5.","journal-title":"Sci. Rep"},{"key":"4212_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1245\/s10434-017-6241-4","volume":"25","author":"A Gaitanidis","year":"2018","unstructured":"A Gaitanidis, D Patel, N Nilubol, A Tirosh, S Sadowski, E Kebebew, Markers of systemic inflammatory response are prognostic factors in patients with pancreatic neuroendocrine tumors (PNETs): a prospective analysis. Ann. Surg. Oncol. 25, 122\u2013130 (2018). https:\/\/doi.org\/10.1245\/s10434-017-6241-4.","journal-title":"Ann. Surg. Oncol."},{"key":"4212_CR14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10147-017-1111-4","volume":"22","author":"K Arima","year":"2017","unstructured":"K Arima, H Okabe, D Hashimoto, A Chikamoto, H Nitta, T Higashi, T Kaida, K Yamamura, Y Kitano, Y Komohara, YI Yamashita, T Beppu, M Takeya, H Baba, Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors. Int. J. Clin. Oncol. 22, 734\u2013739 (2017). https:\/\/doi.org\/10.1007\/s10147-017-1111-4.","journal-title":"Int. J. Clin. Oncol."},{"key":"4212_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.pan.2019.08.003","volume":"19","author":"N Harimoto","year":"2019","unstructured":"N Harimoto, K Hoshino, R Muranushi, K Hagiwara, T Yamanaka, N Ishii, M Tsukagoshi, T Igarashi, H Tanaka, A Watanabe, N Kubo, K Araki, Y Hosouchi, H Suzuki, K Arakawa, K Hirai, T Fukazawa, H Ikota, K Shirabe, Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages. Pancreatology 19, 897\u2013902 (2019). https:\/\/doi.org\/10.1016\/j.pan.2019.08.003.","journal-title":"Pancreatology"},{"key":"4212_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jso.25629","volume":"120","author":"RZ Panni","year":"2019","unstructured":"RZ Panni, AG Lopez-Aguiar, J Liu, GA Poultsides, FG Rocha, WG Hawkins, SM Strasberg, NA Trikalinos, S Maithel, RC Fields, Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG). J. Surg. Oncol. 120, 632\u2013638 (2019). https:\/\/doi.org\/10.1002\/jso.25629.","journal-title":"J. Surg. Oncol."},{"key":"4212_CR17","doi-asserted-by":"publisher","first-page":"42045","DOI":"10.18632\/oncotarget.9805","volume":"7","author":"LL Cao","year":"2016","unstructured":"LL Cao, J Lu, JX Lin, CH Zheng, P Li, JW Xie, JB Wang, QY Chen, M Lin, RH Tu, CM Huang, A novel predictive model based on preoperative blood neutrophil-to-lymphocyte ratio for survival prognosis in patients with gastric neuroendocrine neoplasms. Oncotarget 7, 42045\u201342058 (2016). https:\/\/doi.org\/10.18632\/oncotarget.9805.","journal-title":"Oncotarget"},{"key":"4212_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1210\/jc.2018-01214","volume":"104","author":"JRM Black","year":"2019","unstructured":"JRM Black, SR Atkinson, A Singh, J Evans, R Sharma, The Inflammation-based index can predict response and improve patient selection in NETs treated with PRRT: a pilot study. J. Clin. Endocrinol. Metab. 104, 285\u2013292 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01214.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4212_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12020-022-03133-5","volume":"78","author":"BAM de Lima","year":"2022","unstructured":"BAMde Lima, RGda Silva, C Carroll, B Vilhena, C Perez, R Felix, M Carneiro, LM Neto, F Vaisman, R Corbo, PB Pujatti, D Bulzico, Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients. Endocrine 78, 177\u2013185 (2022). https:\/\/doi.org\/10.1007\/s12020-022-03133-5.","journal-title":"Endocrine"},{"key":"4212_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.remnie.2023.02.006","volume":"42","author":"E Abou-Jokh Casas","year":"2023","unstructured":"E Abou-Jokh Casas, N Mart\u00ednez-Lago, MC Mall\u00f3n Araujo, JM Cabezas Agr\u00edcola, Z Nogareda Seoane, A Cousillas Casti\u00f1eira, A Ruibal Morell, V Pubul N\u00fa\u00f1ez, Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis. Rev. Esp. Med. Nucl. Imagen Mol. 42, 156\u2013162 (2023). https:\/\/doi.org\/10.1016\/j.remnie.2023.02.006.","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol."},{"key":"4212_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney, L Rubinstein, L Shankar, L Dodd, R Kaplan, D Lacombe, J Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009). https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur. J. Cancer"},{"key":"4212_CR22","unstructured":"R Core Team, R: a language and environment for statistical computing (2022). https:\/\/www.R-project.org\/."},{"key":"4212_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"EL Kaplan, P Meier, Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"4212_CR24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","volume":"19","author":"TR Halfdanarson","year":"2008","unstructured":"TR Halfdanarson, KG Rabe, J Rubin, GM Petersen, Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19, 1727\u20131733 (2008). https:\/\/doi.org\/10.1093\/annonc\/mdn351.","journal-title":"Ann. Oncol."},{"key":"4212_CR25","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/cncr.23883","volume":"113","author":"O Hauso","year":"2008","unstructured":"O Hauso, BI Gustafsson, M Kidd, HL Waldum, I Drozdov, AK Chan, IM Modlin, Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113, 2655\u20132664 (2008). https:\/\/doi.org\/10.1002\/cncr.23883.","journal-title":"Cancer"},{"key":"4212_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23808993.2023.2211090","volume":"8","author":"S Loharkar","year":"2023","unstructured":"S Loharkar, S Basu, Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches. Expert. Rev. Precis. Med. Drug. Dev. 8, 1\u201332 (2023). https:\/\/doi.org\/10.1080\/23808993.2023.2211090.","journal-title":"Expert. Rev. Precis. Med. Drug. Dev."},{"key":"4212_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","volume":"50","author":"S Basu","year":"2020","unstructured":"S Basu, RV Parghane, Kamaldeep, S. Chakrabarty, Peptide receptor radionuclide therapy of neuroendocrine tumors. Semin. Nucl. Med. 50, 447\u2013464 (2020). https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.05.004.","journal-title":"Semin. Nucl. Med."},{"key":"4212_CR28","doi-asserted-by":"publisher","first-page":"e19304","DOI":"10.1097\/md.0000000000019304","volume":"99","author":"LF Wang","year":"2020","unstructured":"LF Wang, L Lin, MJ Wang, Y Li, The therapeutic efficacy of 177Lu-DOTATATE\/DOTATOC in advanced neuroendocrine tumors: a meta-analysis. Medicine 99, e19304 (2020). https:\/\/doi.org\/10.1097\/md.0000000000019304.","journal-title":"Medicine"},{"key":"4212_CR29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","volume":"146","author":"J Zhang","year":"2020","unstructured":"J Zhang, Q Song, L Cai, Y Xie, Y Chen, The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 146, 1533\u20131543 (2020). https:\/\/doi.org\/10.1007\/s00432-020-03181-2.","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"4212_CR30","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.ccr-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"T Brabander, WA van der Zwan, JJM Teunissen, BLR Kam, RA Feelders, WW de Herder, CHJ van Eijck, GJH Franssen, EP Krenning, DJ Kwekkeboom, Long-Term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23, 4617\u20134624 (2017). https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2743","journal-title":"Clin. Cancer Res."},{"key":"4212_CR31","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"JR Strosberg, ME Caplin, PL Kunz, PB Ruszniewski, L Bodei, A Hendifar, E Mittra, EM Wolin, JC Yao, ME Pavel, E Grande, EVan Cutsem, E Seregni, H Duarte, G Gericke, A Bartalotta, MF Mariani, A Demange, S Mutevelic, EP Krenning, 177Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752\u20131763 (2021). https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol."},{"key":"4212_CR32","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/pharmaceutics14102009","volume":"14","author":"L Urso","year":"2022","unstructured":"L Urso, S Panareo, A Castello, MR Ambrosio, MC Zatelli, M Caracciolo, E Tonini, G Valpiani, A Boschi, L Uccelli, C Cittanti, M Bartolomei, Glucose metabolism modification induced by radioligand therapy with [177Lu]Lu\/[90Y]Y-DOTATOC in advanced neuroendocrine neoplasms: a prospective pilot study within FENET-2016 trial. Pharmaceutics 14, 2009 (2022). https:\/\/doi.org\/10.3390\/pharmaceutics14102009.","journal-title":"Pharmaceutics"},{"key":"4212_CR33","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"H Gonzalez, C Hagerling, Z Werb, Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes. Dev. 32, 1267\u20131284 (2018). https:\/\/doi.org\/10.1101\/gad.314617.118.","journal-title":"Genes. Dev."},{"key":"4212_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"H Zhao, L Wu, G Yan, Y Chen, M Zhou, Y Wu, Y Li, Inflammation and tumor progression: signaling pathways and targeted intervention. Signal. Transduct. Target. Ther. 6, 263 (2021). https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Signal. Transduct. Target. Ther."},{"key":"4212_CR35","doi-asserted-by":"publisher","first-page":"e3796","DOI":"10.1210\/clinem\/dgab238","volume":"106","author":"P Marques","year":"2021","unstructured":"P Marques, Fde Vries, OM Dekkers, M Korbonits, NR Biermasz, AM Pereira, Serum inflammation-based scores in endocrine tumors. J. Clin. Endocrinol. Metab. 106, e3796\u2013e3819 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab238.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4212_CR36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3390\/diagnostics12030737","volume":"12","author":"D Oh","year":"2022","unstructured":"D Oh, JS Pyo, KH Chung, BK Son, The predicting role of the neutrophil-to-lymphocyte ratio for the tumor grade and Prognosis in pancreatic neuroendocrine tumors. Diagnostics 12, 737 (2022). https:\/\/doi.org\/10.3390\/diagnostics12030737.","journal-title":"Diagnostics"},{"key":"4212_CR37","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.21873\/anticanres.12809","volume":"38","author":"T Fujii","year":"2018","unstructured":"T Fujii, K Yanai, S Tokuda, Y Nakazawa, S Kurozumi, S Obayashi, R Yajima, T Hirakata, K Shirabe, Relationship between FDG uptake and neutrophil\/lymphocyte ratio in patients with invasive ductal breast cancer. Anticancer. Res. 38, 4927\u20134931 (2018). https:\/\/doi.org\/10.21873\/anticanres.12809.","journal-title":"Anticancer. Res."},{"key":"4212_CR38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1186\/s12885-018-5051-9","volume":"18","author":"W Goto","year":"2018","unstructured":"W Goto, S Kashiwagi, Y Asano, K Takada, K Takahashi, T Hatano, T Takashima, S Tomita, H Motomura, K Hirakawa, M Ohira, Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer 18, 1137 (2018). https:\/\/doi.org\/10.1186\/s12885-018-5051-9.","journal-title":"BMC Cancer"},{"key":"4212_CR39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"A Mantovani, P Allavena, F Marchesi, C Garlanda, Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug. Discov. 21, 799\u2013820 (2022). https:\/\/doi.org\/10.1038\/s41573-022-00520-5.","journal-title":"Nat. Rev. Drug. Discov."},{"key":"4212_CR40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/1055-9965.epi-18-1066","volume":"28","author":"YH Choi","year":"2019","unstructured":"YH Choi, JW Lee, SH Lee, JH Choi, J Kang, BS Lee, WH Paik, JK Ryu, YT Kim, A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with advanced gallbladder cancer receiving chemotherapy. Cancer Epidemiol. Biomark. Prev. 28, 1045\u20131051 (2019). https:\/\/doi.org\/10.1158\/1055-9965.epi-18-1066.","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"4212_CR41","doi-asserted-by":"publisher","first-page":"638312","DOI":"10.3389\/fcell.2021.638312","volume":"9","author":"X Fan","year":"2021","unstructured":"X Fan, D Wang, W Zhang, J Liu, C Liu, Q Li, Z Ma, H Li, X Guan, Y Bai, J Yang, C Lou, X Li, G Wang, Z Li, Inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti-PD-1 therapy. Front. Cell Dev. Biol. 9, 638312 (2021). https:\/\/doi.org\/10.3389\/fcell.2021.638312.","journal-title":"Front. Cell Dev. Biol."},{"key":"4212_CR42","doi-asserted-by":"publisher","first-page":"21262","DOI":"10.1038\/s41598-023-47874-3","volume":"13","author":"SI Moukas","year":"2023","unstructured":"SI. Moukas, S. Kasimir-Bauer, M. Tewes, HC. Kolberg, O. Hoffmann, R. Kimmig, C. Keup,, Ratios ofmonocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4\/6 inhibitor treatmentin metastatic breast cancer. Sci. Rep 13, 21262 (2023). https:\/\/doi.org\/10.1038\/s41598-023-47874-3.","journal-title":"Sci. Rep"},{"key":"4212_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PPO.0b013e3181bdc2e0","volume":"15","author":"JJ Driscoll","year":"2009","unstructured":"JJ Driscoll, O Rixe, Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J. 15, 401\u2013405 (2009). https:\/\/doi.org\/10.1097\/PPO.0b013e3181bdc2e0.","journal-title":"Cancer J."},{"key":"4212_CR44","doi-asserted-by":"publisher","first-page":"e2144170","DOI":"10.1001\/jamanetworkopen.2021.44170","volume":"5","author":"S Das","year":"2022","unstructured":"S Das, A Chauhan, L Du, KE Thomas, A Jacob, A Schad, S Jain, A Jessop, C Shah, D Eisner, DB Cardin, KK Ciombor, LW Goff, M Bradshaw, D Delbeke, M Sandler, RA Ramirez, J Berlin, External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy. JAMA Netw. Open. 5, e2144170 (2022). https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44170.","journal-title":"JAMA Netw. Open."},{"key":"4212_CR45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.122.264363","volume":"64","author":"L Bodei","year":"2023","unstructured":"L Bodei, N Raj, RK Do, A Mauguen, S Krebs, D Reidy-Lagunes, H Sch\u00f6der, Interim analysis of a prospective validation of 2 blood-based genomic assessments (PPQ and NETest) to Determine the clinical efficacy of (177)Lu-DOTATATE in neuroendocrine tumors. J. Nucl. Med. 64, 567\u2013573 (2023). https:\/\/doi.org\/10.2967\/jnumed.122.264363.","journal-title":"J. Nucl. Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04212-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04212-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04212-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:49:09Z","timestamp":1751611749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04212-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4212"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04212-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed and approved by the Scientific Advisory Committee (SAC) and Institutional Ethics Committee (IEC) of the Radiation Medicine Centre. The informed consent was waived by the Institutional Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}